Viva Biotech Expands Pharmacology Platform to Support Diverse Drug Modalities
I'm PortAI, I can summarize articles.
Viva Biotech Holdings has expanded its pharmacology platform, enhancing DMPK, pharmacology, and efficacy services. The company invested in facility expansion and integrated antibody pharmacokinetics with disease-focused studies, supporting diverse drug modalities. This platform offers end-to-end services from discovery to IND filing, enabling data-driven decisions in preclinical drug development. The news was published by Viva Biotech Holdings via PR Newswire on December 29, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments